Qiagen posted revenues of $396.9 million in Q4 compared to $366.5 million a year ago and beat analysts' estimates on both the top and bottom lines.
Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.
Researchers found methylation mediators of obesity and other metabolic features by profiling individuals born after a famine called the Dutch Hunger Winter.
The clinicals labs contributing to the database are adding more case-level data and focusing on outlier interpretations.
The firm said its columns, which use patterned silicon wafers, improve on existing LC systems in terms of robustness, reproducibility, and depth of separation.
A study published in Nature this week is the latest to suggest that blood-based protein markers could be indicative of amyloid deposit levels in the brain.
Biodesix will work with university researchers on an assay to help identify non-small cell lung cancer patients likely to respond to certain immunotherapies.
Illumina plans to develop clinical-grade products and expects that reimbursement and regulatory trends will further drive growth of its technology in the clinic.
The polygenic score snags a greater percentage of people at risk of early heart attack than current tests that rely on single-gene variants or blood chemistry.
The partners are developing and optimizing an algorithm that assesses the likelihood of a patient's cancer progressing to metastasis.
A Max Planck-led team sequenced three dozen ancient humans found in the Baltic to unravel the region's population history.
The partnership will integrate Ambry Genetics' and Invicro's technologies to expedite new drug discovery and development.
The financing will be used to advance the firm's drug discovery platform, which combines high-throughput wet lab experimentation with artificial intelligence.
The Fraunhofer USA team will partner with a Fraunhofer Society institute in Germany in order to reduce the cost for its patented microchip that detects viruses including Ebola.
The firm plans to use the $13.3 million in net proceeds to fund ongoing operations, expansions of its liquid biopsy business, and to service its indebtedness.
Liquid biopsy companies are increasingly recognizing the value of analyzing not just circulating tumor DNA, but biomarkers like CTCs, methylation, and proteins.
As organisms age, their transcriptomic signatures shift from looking more like those observed in cancer to those seen in degenerative chronic diseases.